Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04902781 · ClinicalTrials.gov registry record · Phase 2
Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia
A Phase 2 study, sponsored by Applied Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT04902781 is a Phase 2 study that has completed, run by Applied Therapeutics. The registered enrollment target is 47 participants.
The verdict
NCT04902781, a Phase 2 study, has completed, sponsored by Applied Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This study is designed to assess the clinical benefit as well as the safety, pharmacokinetics (PK), and pharmacodynamics (PD) (reduction of galactitol levels) of AT-007 in pediatric subjects with Classic Galactosemia (CG).
Interventions
- OTHER Placebo
- DRUG AT-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2021-03-20 |
| Est. Completion | 2025-05-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04902781
The ClinicalTrials.gov registry entry for NCT04902781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Applied Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04902781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04902781 about?
NCT04902781 is a clinical study titled "Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia". This study is designed to assess the clinical benefit as well as the safety, pharmacokinetics (PK), and pharmacodynamics (PD) (reduction of galactitol levels) of AT-007 in pediatric subjects with Classic Galactosemia (CG).
What is the current status of trial NCT04902781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2021-03-20. Estimated completion is 2025-05-21.
What interventions are being tested in trial NCT04902781?
The interventions under investigation include: Placebo (OTHER), AT-007 (DRUG).
Who is sponsoring clinical trial NCT04902781?
This trial is sponsored by Applied Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.